Table 2. Twenty largest decreases in RNA expression between prostate tumor and non-malignant TCGA samples.
| Gene Symbol | Name | Log2 Fold Change | P-value | Q-value |
|---|---|---|---|---|
| WFDC9 | Protein WFDC9 | -11.89 | 1.98E-04 | 4.30E-04 |
| DEFB125 | Beta-defensin 125 | -10.91 | 4.30E-04 | 8.89E-04 |
| EDDM3B | Epididymal secretory protein E3-beta | -10.85 | 4.64E-09 | 1.96E-08 |
| PAEP | Glycodelin | -10.82 | 3.47E-16 | 3.78E-15 |
| SEMG2 | Semenogelin-2 | -10.64 | 1.98E-63 | 2.36E-60 |
| PATE4 | Prostate and testis expressed protein 4 | -10.48 | 2.26E-55 | 1.54E-52 |
| EDDM3A | Epididymal secretory protein E3-alpha | -10.45 | 5.77E-13 | 4.05E-12 |
| CRISP1 | Cysteine-rich secretory protein 1 | -9.58 | 1.17E-25 | 5.02E-24 |
| PATE1 | Prostate and testis expressed protein 1 | -9.53 | 3.27E-27 | 1.76E-25 |
| DEFB127 | Beta-defensin 127 | -9.52 | 1.06E-04 | 2.41E-04 |
| AQP2 | Aquaporin-2 | -9.50 | 1.94E-57 | 1.69E-54 |
| TMEM114 | Transmembrane protein 114 | -9.35 | 1.19E-15 | 1.21E-14 |
| GRXCR1 | Glutaredoxin domain-containing cysteine-rich protein 1 | -8.75 | 5.95E-19 | 9.64E-18 |
| SPINT3 | Kunitz-type protease inhibitor 3 | -8.23 | 2.11E-24 | 7.48E-23 |
| CLDN2 | Claudin-2 | -8.02 | 2.11E-75 | 6.72E-72 |
| SULT2A1 | Bile salt sulfotransferase | -7.98 | 9.41E-20 | 1.70E-18 |
| SPINK2 | Serine protease inhibitor Kazal-type 2 | -7.71 | 5.75E-71 | 8.46E-68 |
| POU3F3 | POU domain, class 3, transcription factor 3 | -7.70 | 4.68E-17 | 5.77E-16 |
| LCN1 | Lipocalin-1 | -7.66 | 4.18E-08 | 1.56E-07 |
| PATE3 | Prostate and testis expressed protein 3 | -7.63 | 3.33E-25 | 1.32E-23 |
Log2 fold change describes malignant expression relative to non-malignant expression. P-value is determined by DESeq2 using Wald Statistics and Q-value is the false discovery rate-adjusted P-value.